EXEL - Exelixis Inc logo

EXEL

Exelixis Inc

Net income grew 100% of yearsRevenue grew 100% of years1Y
Compare EXEL Hold

Exelixis, Inc. develops and commercializes targeted therapies for cancer, primarily focusing on advanced renal cell carcinoma and medullary thyroid cancer. Its key products include CABOMETYX and COMETRIQ, both derived from cabozantinib, a kinase inhibitor.

โš•๏ธ Healthcare NASDAQ Listed 2000 $ USD
$1,000 invested 1 year ago โ†’$1,495today

Score Overview

1 Year
Score
Net Growth9.97%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth4.99%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score8.4
Net Growth272.46%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth69.75%
Rev TrendEvery year
Revenue Consistencyโ€”
10 Years
Score
Net Growth14x
Net Trend70%
Net Income Consistency
Rev Growth12x
Rev TrendEvery year
Revenue Consistency
20 Years
Score6.3
Net Growth10x
Net Trend65%
Net Income Consistency
Rev Growth24x
Rev Trend85%
Revenue Consistency
All Time
Score
Net Growth13x
Net Trend58%
Net Income Consistency
Rev Growth98x
Rev Trend88%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Exelixis Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • EXEL

2011: 60.4% ยท 2021: 46.5% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 58.37โ€”
1 Year2025-09-26
$ 39.0449.51%
5 Years2021-09-28
$ 20.60183.35%
10 Years2016-09-28
$ 13.35337.23%
20 Years2006-09-28
$ 9.036x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 2.43B$ 860M$ 839M
2025$ 2.32B$ 782M$ 1.05B
2024$ 2.16B$ 521M$ 1.11B
2023$ 1.83B$ 207M$ 995M
2022$ 1.61B$ 182M$ 1.30B
2021$ 1.43B$ 231M$ 1.46B
2020$ 987M$ 111M$ 1.20B
2019$ 967M$ 321M$ 852M
2018$ 853M$ 690M$ 693M
2017$ 452M$ 154M$ 387M
2016$ 191M-$ 70M$ 419M
2015$ 37M-$ 169M$ 167M
2014$ 25M-$ 268M$ 144M
2013$ 31M-$ 244M$ 242M
2012$ 47M-$ 147M$ 411M
2011$ 289M$ 75M$ 194M
2010$ 185M-$ 92M$ 162M
2009$ 151M-$ 135M$ 203M
2008$ 117M-$ 162M$ 262M
2007$ 113M-$ 86M$ 271M
2006$ 98M-$ 101M$ 178M
2005$ 75M-$ 84M$ 163M
2004$ 52M-$ 137M$ 155M
2003$ 51M-$ 94M$ 237M
2002$ 44M-$ 86M$ 216M
2001$ 41M-$ 71M$ 227M
IPO2000$ 24M-$ 75M$ 112M
EXEL - Exelixis Inc logo

Exelixis Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 987M to $ 2.32B and net income grew from $ 111M to $ 782M. Revenue increased in every one of those 5 years; net income in 4.

Between 2015 and 2025, revenue grew from $ 37M to $ 2.32B and net income went from -$ 169M to $ 782M. Revenue increased in every one of those 10 years; net income in 7.

Exelixis Inc currently holds a 20-year HDB Score of 6.3 out of 10. How the HDB Score is calculated.

Membership

Continue EXELโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies